Company intelligence / Profile preview

BioKobe

Ownership: Private
Development stage: Commercial

Overview

BioKobe developed a durable polymer scaffold for cartilage repair, collaborating with a European partner using chondrocyte culturing. The combined product underwent limited clinical trials under Japan’s conditional approval track, followed by expanded Phase II trials across multiple hospitals. The product received regulatory approval from Japan’s MHLW for broader use and achieved modest but steady market share domestically and regionally. Ongoing R&D continues with stable revenues reported from structured royalty agreements with the European partner.

Therapeutic areas: Rheumatology
Modalities: Scaffold-based therapyPolymer-based medical deviceCell therapy
Industry: Biotech

Partnerships

European biotech company specializing in chondrocyte culturing/cartilage therapies (name not disclosed)

Beyond the preview

Go deeper on BioKobe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioKobe.

Explore the full profile